The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. (Record no. 20991441)

MARC details
000 -LEADER
fixed length control field 02215 a2200589 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250516044800.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201205s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1432-1041
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/s00228-011-1094-4
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Azuma, Junichi
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20120504
245 00 - TITLE STATEMENT
Title The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. European journal of clinical pharmacology
Date of publication, distribution, etc. Jan 2012
300 ## - PHYSICAL DESCRIPTION
Extent 29-37 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antipsychotic Agents
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aripiprazole
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biotransformation
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytochrome P-450 CYP2D6
General subdivision genetics
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytochrome P-450 CYP2D6 Inhibitors
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytochrome P-450 CYP3A
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytochrome P-450 CYP3A Inhibitors
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Interactions
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Enzyme Inhibitors
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Fluvoxamine
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Genetic Association Studies
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Half-Life
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Japan
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Metabolic Clearance Rate
General subdivision drug effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Paroxetine
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Piperazines
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Polymorphism, Genetic
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Quinolones
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Serotonin 5-HT2 Receptor Antagonists
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Selective Serotonin Reuptake Inhibitors
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Young Adult
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Hasunuma, Tomoko
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Kubo, Masanori
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Miyatake, Masaya
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Koue, Toshiko
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Higashi, Koushi
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Fujiwara, Tsutomu
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Kitahara, Sachiko
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Katano, Tamiki
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Hara, Sumiko
773 0# - HOST ITEM ENTRY
Title European journal of clinical pharmacology
Related parts vol. 68
-- no. 1
-- p. 29-37
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1007/s00228-011-1094-4">https://doi.org/10.1007/s00228-011-1094-4</a>
Public note Available from publisher's website

No items available.